u-PA expression in benign, borderline and malignant ovarian tumors

Anticancer Research

Volumn 22, Issue 2 A, 2002, Pages 985-990

  Kiziridou, A D ^a   Toliou, T ^a   Stefanou, D ^a   Agnantis, N ^a  

^a Theag Anticancer Inst Thessaloniki   (Greece)

Author keywords

Borderline tumors; Immunohistochemistry; Ovarian carcinoma; Plasminogen activator

Indexed keywords

MONOCLONAL ANTIBODY; UROKINASE;

ARTICLE; CANCER RISK; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; METASTASIS; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; STROMA CELL;

ADULT; AGED; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, MUCINOUS; CYSTADENOCARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; CYSTADENOMA, MUCINOUS; CYSTADENOMA, SEROUS; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036253336     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells
2. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumors
3. The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma
4. Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum
5. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer
6. The plasminogen-activation system in ovarian tumors
7. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers
8. Urokinase and plasminogen activator inhibitor type-1 in pulmonary adenocarcinoma
9. Plasminogen activation system is active even in thyroid tumors; An immunohistochemical study
10. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression
11. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma
12. Metastastic machinations
13. Urokinase (u-PA) is a strong independent prognostic factor in node-negative breast cancer
14. Plasminogen activators in endoscopic biopsies as indicator of gastrointestinal cancer: Comparison with resection specimens
15. Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissue
16. Coordinate expression of urinary-type plasminogn activator and its receptor accompanies malignant transformation of the ovarian surface epithelium
17. Immunohistochemical evidence of urokinase type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma
18. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas
19. Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine- proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment
20. The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors